Identification of a Novel Structural Class of HV1 Inhibitors by Structure-Based Virtual Screening

Martina Piga1, Zoltan Varga2, Adam Feher2

  • 1Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.

Insights

Researchers identified new inhibitors for the human voltage-gated proton channel (hHV1), a target for cancer and inflammatory diseases. Compound 13 and its analogs show promise for therapeutic development.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Ion Channel Biology

Background:

  • The human voltage-gated proton channel (hHV1) is implicated in cancer metastasis, neuroinflammation, immune disorders, and infertility.
  • Overexpression of hHV1 in cancer cells suggests its potential as a therapeutic target.

Purpose of the Study:

  • To identify novel inhibitors of the hHV1 channel using structure-based virtual screening.
  • To investigate the structure-activity relationships (SAR) of identified inhibitors.
  • To evaluate the antiproliferative effects of hHV1 inhibitors in cancer cell lines.

Main Methods:

  • Structure-based virtual screening of compounds against an open hHV1 channel structure.
  • In vitro testing of virtual screening hits and analogs on hHV1-expressing CHO cells.
  • Determination of IC50 values for proton current block.
  • Assessment of antiproliferative activity in MDA-MB-231 and THP-1 cancer cell lines.

Main Results:

  • Compound 13 demonstrated potent hHV1 channel block with an IC50 of 8.5 μM.
  • Further optimization yielded six additional compounds with significant proton current inhibition.
  • Compound 13 exhibited antiproliferative effects with IC50 values of 9.0 μM and 8.1 μM in MDA-MB-231 and THP-1 cells, respectively.
  • Structure-activity relationship analysis provided insights into inhibitor design.

Conclusions:

  • A new structural class of hHV1 inhibitors was identified.
  • These findings enhance understanding of hHV1 inhibition mechanisms.
  • The identified compounds represent potential leads for therapeutic strategies in cancer and other hHV1-related pathologies.